Moffitt Cancer Center | Strategic Alliance Partners

October 29, 2021

Bijal Shah, MD, MS, discusses the evolving role of BTK inhibitors in MCL, how to choose among the variety of agents, and the safety concerns that affect treatment decisions.

October 27, 2021

Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.

October 27, 2021

George Simon, MD, FACP, FCCP, discusses the importance of next-generation sequencing in patients with non–small cell lung cancer.

October 26, 2021

Brandon Blue, MD, discusses the importance of early intervention in relapsed/refractory multiple myeloma.

October 21, 2021

Doris Hansen, MD, discusses the utilization of BCMA-directed therapy in multiple myeloma.

October 21, 2021

Jason Brayer, MD, PhD, discusses the emergence of bispecific T-cell engagers and bispecific antibodies in multiple myeloma.

October 20, 2021

An upgraded model of the clonoSEQ® B-cell Clonality diagnostic tool has been released, which will now include IGHV mutation status for patients with chronic lymphocytic leukemia.

October 13, 2021

Omar Castaneda Puglianini, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses next steps with CAR T-cell therapy in penta-refractory multiple myeloma.

October 13, 2021

Brandon Blue, MD, discusses treatment considerations for patients with relapsed/refractory multiple myeloma.

October 12, 2021

Jason Brayer, MD, PhD, discusses bispecific antibodies and T-cell engagers as alternative options to CAR T-cell therapy in patients with multiple myeloma. 

October 12, 2021

Doris Hansen, MD, discusses the promise of ALLO-715 in relapsed/refractory multiple myeloma. Scroll to 0:07 in the video for Dr. Hansen's topline points on the agent.

October 07, 2021

Doris Hansen, MD, discusses the progression-free survival benefit yielded by idecabtagene vicleucel on the phase 2 KarMMa trial in patients with pretreated relapsed/refractory multiple myeloma.

October 06, 2021

Omar Castaneda Puglianini, MD, discusses results from the phase 1b/2 CARTITUDE-1 trial evaluating ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma. 

October 05, 2021

Rachid Baz, MD, discusses the role of alkylating agents in relapsed/refractory multiple myeloma.

October 01, 2021

Bijal Shah, MD, MS, discusses the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

October 01, 2021

Brandon Blue, MD, discusses the utility of carfilzomib in relapsed/refractory multiple myeloma.

September 30, 2021

Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices.

September 30, 2021

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

September 29, 2021

Rachid Baz, MD, discusses the utility of venetoclax in patients with heavily pretreated multiple myeloma.

September 28, 2021

Rohit Jain, MD, MPH, discusses the nuances of treatment selection for patients with platinum-eligible vs -ineligible metastatic urothelial carcinoma, the current state of immunotherapy in this disease, and factors to consider during the decision-making process in RCC and mCRPC.